FORMULATION DEVELOPMENT AND IN-VITRO EVELUATION OF SUSTAINED RELEASE TABLETS OF REPAGLINIDE
*N. Rajitha, R. Sunitha, V. Lokesh Babu and A. Srinivasa Rao
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin dependent diabetes mellitus
(NIDDM). Repaglinide is an amino acid derivative that induces an early insulin response to meals decreasing
postprandial blood glucose levels. The major problem in oral drug formulations is low and erratic bioavailability,
which mainly results from poor aqueous solubility. Solid dispersions is the techniques and the most attractive
processes to improve solubility of poorly soluble drugs. Here the solubility of Repaglinide is enhanced by solid
dispersions with PEG 6000 and urea as carriers. Among the various solid dispersions prepared, the formulation
FSDPN3 i.e., the solid dispersion of Repaglinide with PEG6000 prepared by Fusion method shows faster
dissolution rate it was decided to use formulations FSDPN3 to formulate sustained release tablets using different
polymers like HPMC, EC ,Guar gum and Xanthum gum by direct compression technique. Among the various
sustained release tablets of Repaglinide solid dispersion prepared, the formulation F2 shows complete release of
drug in 12 hrs, which is considered as best formulation for sustained release tablets of Repaglinide.
Keywords: Antihyperglycemic, postprandial, xanthum gum, direct compression technique.
[Full Text Article]